Background and AimDrug‐induced autoimmune hepatitis (DIAIH) is an adverse effect associated with several drugs that usually occurs acutely, with variable latency, and it may potentially be mortal. There are a few reports and studies about DIAIH.MethodsThis was an analytical study of a retrospective cohort of patients, discriminated according to idiopathic or drug‐induced etiology, followed up for a 7‐year period until 31 December 2016.ResultsA total of 190 patients were selected for the analysis, 12 (6.3%) with DIAIH. The two main drugs related to DIAIH were nitrofurantoin, n = 8 (67%), and NSAID, n = 2 (17%), constituting 84% of the cases. There were no significant differences in seropositivity between AIH with DIAIH in antinuclear antibodies (ANA) and anti‐smooth muscle antibodies (ASMA) antibodies, with 82.6% versus 82.6% and 34% versus 16%, respectively. The fibrosis stages were similar, except for the F4 stage, in a greater proportion in AIH. None of the patients with DIAIH had cirrhosis or developed it during follow‐up, but it was present in 42.1% of the AIH cases at diagnosis (P = 0.003). Biochemical remission with management was higher in DIAIH but not significant (91.7% vs 80.9%, P = 0.35). The definitive interruption of immunosuppression was successfully performed in 25% of those with DIAIH without relapses but was only possible in 2.8% in AIH (P < 0.001) with 32 cases of relapses.ConclusionDIAIH constitutes a minor proportion of AIH. The clinical and histological characteristics may be similar; DIAIH patients have a greater chance of having treatment suspended with a low risk of relapse, progression to cirrhosis, or need for liver transplant.
Introducción. La infección crónica por el virus de la hepatitis C es un problema de salud pública y se estima que hay más de 180 millones de personas infectadas en el mundo. En Colombia no se conoce la epidemiología de la infección ni los genotipos virales más frecuentes. Objetivo. Describir los genotipos y subtipos del virus de la hepatitis C en pacientes colombianos infectados. Materiales y métodos. Se hizo un estudio descriptivo y retrospectivo de pruebas realizadas en dos laboratorios de referencia nacional, entre el 2003 y el 2015, mediante electroforesis en geles de poliacrilamida (Polyacrylamide Gel Electrophoresis, PAGE) o reacción en cadena de la polimerasa en tiempo real (quantitative PCR, qPCR). Resultados. Se estudiaron 1.538 aislamientos del virus de la hepatitis C de 1.527 pacientes con una edad promedio de 53 años, de los cuales 70 % tenía entre 40 y 70 años y 52 % eran mujeres. El 57 % de las pruebas se ordenaron en la ciudad de Bogotá, y el 80 % de los casos provenía de los departamentos de Cundinamarca, Valle y Atlántico. Se encontró el genotipo 1 en 88,6 % de los casos, distribuido así: subtipo 1b, 70 %, subtipo 1a, 13,5 %, y no determinado, 5,1 % de los casos; el genotipo 2 se encontró en el 5,4 % de los casos, el 3, en el 2 %, y el 4, en el 4 %. Se encontraron genotipos mixtos en 0,8 % de la muestra. Conclusión. El genotipo 1 del virus de la hepatitis C es el que circula con mayor frecuencia en el país, con predominio del subtipo 1b.Palabras clave: hepatitis C/genética; hepacivirus; genotipo; epidemiología; reacción en cadena de la polimerasa. doi: http://dx.doi.org/10.7705/biomedica.v37i1.3173 Hepatitis C virus genotypes circulating in ColombiaIntroduction: Chronic hepatitis C virus infection is a worldwide public health problem; it has been estimated that over 180 million people are infected with this virus worldwide. Its precise incidence and prevalence (i.e., epidemiology) and the most frequent circulating genotypes in Colombia are unknown. Objective: To describe the hepatitis C virus (HCV) genotypes and subtypes in infected Colombian patients. Materials and methods:We recovered the data on 1,538 HCV isolates from 1,527 patients in two Colombian reference laboratories typed by PAGE or qPCR. Results: Patients' mean age was 53 years; 70% of them were 40 to 70 years old, and 52%, females; 57% of all tests were ordered in Bogotá and 80% of cases were from Cundinamarca, Valle and Atlántico departments. Genotype 1 was detected in 88.6% of cases, distributed as follows: 70% subtype 1b, 13.5% subtype 1a and 5.1%, undetermined subtypes. Genotype 2 was found in 5.4% of the patients, genotype 3 in 2% and genotype 4 in 4%. Mixed genotypes were found in 0.8% of the samples. Conclusion: Genotype 1 is the most common HCV genotype circulating in Colombia, and subtype 1b the most frequent.
Objectives: Liver transplantation is the treatment of choice for acute and chronic liver failure, for selected cases of tumors, and for conditions resulting from errors in metabolism. This paper reports the experience of a medical center in Latin America.Methods: Were conducted 305 orthotopic liver transplantations on 284 patients between 2004 and 2010. Of these patients, 241 were adults undergoing their first transplantation.Results: The average age of patients was 52 years old, and 62% of the individuals were male. The most common indication was alcoholic cirrhosis. The rate of patient survival after 1 and 5 years was 82 and 72% respectively. The rate of liver graft survival after 1 and 5 years was 78 and 68% respectively. The main cause of death was sepsis. Complications in the hepatic artery were documented for 5% of the patients. Additionally, 14.5% of the patients had complications in the biliary tract. Infections were found in 41% of the individuals. Acute rejection was observed in 30% of the subjects, and chronic rejection in 3%. Conclusion: In conclusion, liver transplantation at our medical center in Colombia offers good mid-term results, with a complication rate similar to that reported by other centers around the world.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.